Welcome to our dedicated page for Unity Btech SEC filings (Ticker: UBX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Unity Biotechnology, Inc.’s SEC filings for the historical Nasdaq symbol UBX and the over‑the‑counter symbol UNBX document both its clinical‑stage biotechnology activities and its transition toward dissolution. These filings are central for understanding how the company has described its senolytic and senescence‑modulating programs, its financial position, and the legal steps associated with delisting and winding down.
Through annual and quarterly reports on Form 10‑K and 10‑Q, Unity provides detailed discussions of its focus on therapeutics that selectively eliminate or modulate senescent cells to address age‑related ophthalmologic and neurologic diseases. These reports describe the development of UBX1325 for diabetic macular edema (DME), summarize the design and outcomes of the BEHOLD and ASPIRE clinical studies, and present research and development and general and administrative expenses. Investors can review these filings to see how Unity characterizes its clinical data, pipeline priorities, and cash resources over time.
Current reports on Form 8‑K are particularly important for Unity. A June 27, 2025 Form 8‑K explains Nasdaq’s determination that Unity no longer has an operating business and is a public shell, outlines the company’s notice of delisting, and describes the Board’s approval of a Plan of Dissolution under Delaware law. Subsequent 8‑K and 8‑K/A filings dated July 22 and July 24, 2025 detail the creation and issuance of a single Series A Preferred Share designed solely to vote on the dissolution proposal, as well as the mechanics of that security’s voting rights.
Listing and trading status changes are reflected in a Form 25 filed on August 6, 2025 by The Nasdaq Stock Market LLC, which formally removes Unity Biotechnology’s common stock from listing and registration under Section 12(b) of the Exchange Act. Earlier 8‑K filings describe the suspension of trading on Nasdaq on July 9, 2025 and the commencement of quotations on the OTC Pink Marketplace under the symbol UNBX.
Unity’s definitive proxy statement on Schedule 14A, filed August 11, 2025, is the primary source for information about the proposed liquidation and dissolution. It sets the agenda for a special meeting of stockholders to vote on the Dissolution Proposal and an Adjournment Proposal, outlines the Plan of Complete Liquidation and Dissolution, and discusses risk factors related to the dissolution process. The proxy statement notes that, based on information available at the time of filing, the company expected there would not be any amounts available for distribution to stockholders, while also explaining that the final outcome depends on resolving claims, obligations, and wind‑down expenses.
On Stock Titan’s filings page, users can access these Unity Biotechnology documents as they appear on EDGAR and use AI‑powered summaries to interpret complex sections. For example, AI tools can highlight key elements of Unity’s 10‑K and 10‑Q risk factors, extract the main terms of the Plan of Dissolution from the proxy statement, and clarify the implications of Forms 8‑K and 25 for shareholders. Filings related to insider or control‑person transactions, such as the issuance of the Series A Preferred Share, can also be examined to understand how voting control for the dissolution proposal is structured.
Together, Unity’s SEC filings provide a detailed regulatory record of its evolution from a clinical‑stage biotechnology issuer focused on senolytic ophthalmology programs to a public shell pursuing asset monetization, delisting from Nasdaq, and a planned corporate dissolution under Delaware law.
Unity Biotechnology filed Post-Effective Amendment No. 1 to terminate the effectiveness of multiple Form S-8 registration statements and remove from registration any shares of its common stock that remain unsold under those filings. The amendment lists each affected S-8 by file number and the original registered share amounts for various equity plans, and states the numbers do not reflect any interim corporate actions.
Unity Biotechnology filed Post-Effective Amendment No. 1 to terminate effectiveness of multiple Form S-8 registration statements and remove from registration any and all shares of its common stock that remained unsold under those S-8 filings. The amendment lists ten S-8 registration numbers and the original registered share amounts for various equity plans, and states the Registration Statements are amended to reflect the deregistration.
Unity Biotechnology, Inc. has filed Post-Effective Amendment No. 1 to terminate the effectiveness of multiple Form S-8 registration statements and to remove from registration any shares of the company’s common stock that remain unsold under those registrations. The amendment lists ten prior S-8 filings (from 2018 through March 7, 2025) and specifies the originally registered share amounts for various equity plans. The filings are amended to reflect the deregistration of all unsold securities referenced, noting numbers do not account for subsequent corporate actions.
Unity Biotechnology filed Post-Effective Amendment No. 1 to terminate the effectiveness of multiple Form S-8 registration statements and remove from registration any unsold shares of its common stock previously registered for various equity plans. The amendment lists ten S-8 registrations (from 2018 through 2025) and the original share amounts for each plan, and states the registratio ns are amended to reflect deregistration of all unsold securities.
Unity Biotechnology filed Post-Effective Amendment No. 1 to terminate the effectiveness of multiple Form S-8 registration statements and to remove from registration all unsold shares of its common stock previously registered under those S-8s. The amendment lists ten prior S-8 filings and the original number of shares registered under each plan, and notes the listed totals do not reflect any interim corporate actions such as stock splits.
Unity Biotechnology filed Post-Effective Amendment No. 1 to terminate the effectiveness of multiple Form S-8 registration statements and to remove from registration all unsold shares of its Common Stock previously registered under those statements. The amendment lists each affected S-8 by file number and the specific share amounts tied to various equity plans, and states the registration statements are amended to reflect the deregistration of any securities still unsold as of the filing date.
Unity Biotechnology filed Post-Effective Amendment No. 1 to terminate the effectiveness of multiple Form S-8 registration statements and to remove from registration all shares of its common stock that remained unsold under those registration statements. The amendment lists each affected S-8 (registration numbers and original share allocations by plan) and states the registration statements are amended to reflect deregistration of the unsold securities.
Unity Biotechnology filed Post-Effective Amendment No. 1 to terminate effectiveness of multiple Form S-8 registration statements and remove from registration all shares that remain unsold under those filings. The amendment deregisters unsold common stock previously registered across ten S-8 filings spanning 2018 to 2025, specifying the original registered share amounts for each plan and noting that listed numbers do not reflect subsequent corporate actions such as stock splits.
Unity Biotechnology filed Post-Effective Amendment No. 1 to terminate effectiveness of multiple Form S-8 registration statements and remove from registration all unsold shares of its common stock previously registered under those S-8 filings. The filing lists ten Registration Statements spanning 2018–2025 and specifies the originally registered share amounts for various equity plans such as the 2013 Equity Incentive Plan, 2018 Incentive Award Plan, 2020 Inducement Plan and the 2018 Employee Stock Purchase Plan. The Company states the deregistration reflects removal of all unsold securities as of the filing date.
Unity Biotechnology filed Post-Effective Amendment No. 1 to terminate the effectiveness of multiple Form S-8 registration statements and to remove from registration any and all shares of its common stock that remained unsold under those statements. The amendment lists each affected S-8 by SEC file number and the original registered share amounts for various equity plans, and states the Registration Statements are amended to reflect deregistration of the unsold securities.
FAQ
What is the current stock price of Unity Btech (UBX)?
What is the market cap of Unity Btech (UBX)?
